SCHEMBL11037115

SCHEMBL11037115

CCC(=O)c1ccccc1N1CCCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.60
MAPT P10636 4/20 0.51
ALDH1A1 P00352 4/20 0.50
TSHR P16473 2/20 0.50
HPGD P15428 1/20 0.50
L3MBTL1 Q9Y468 4/20 0.48
ATM Q13315 2/20 0.48
NPSR1 Q6W5P4 3/20 0.46
ABCB1 P08183 3/20 0.46
GAA P10253 3/20 0.46
HCRTR1 O43613 1/20 0.45
HCRTR2 O43614 1/20 0.45
KCNQ2 O43526 3/20 0.45
PTPN1 P18031 2/20 0.45
KCNQ3 O43525 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
KCNE1 P15382 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6569082 0.98 NPC1 (0.63) NPC1MAPTALDH1A1TSHRHPGD
Hydrochloric Acid SCHEMBL10728839 0.97 NPC1 (0.61) NPC1MAPTALDH1A1TSHRHPGD
SCHEMBL9170847 0.85 MAPT (0.48) NPC1MAPTALDH1A1TSHRHPGD
SCHEMBL27777806 0.85 HTR1A (0.52) MAPTALDH1A1ABCB1GAAHTT
SCHEMBL501560 0.85 LMNA (0.53) NPC1MAPTALDH1A1HPGDL3MBTL1
SCHEMBL27818370 0.85 ADRB1 (0.51) NPC1MAPTTSHRCYP1A2CYP2D6
SCHEMBL11665416 0.85 NPC1 (0.59) NPC1MAPTALDH1A1TSHRHPGD
SCHEMBL4936194 0.84 NPC1 (0.54) NPC1MAPTALDH1A1TSHRHPGD
SCHEMBL10854322 0.84 NPC1 (0.50) NPC1MAPTALDH1A1TSHRHPGD
SCHEMBL30457496 0.84 NPC1 (0.54) NPC1MAPTALDH1A1TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260086062-A1 IMMOBILIZATION STRATEGIES FOR ENHANCING SENSITIVITY OF ELECTROCHEMICAL APTAMER-BASED SENSORS THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2026-03-26 US claimed
US-20260086062-A1 IMMOBILIZATION STRATEGIES FOR ENHANCING SENSITIVITY OF ELECTROCHEMICAL APTAMER-BASED SENSORS THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2026-03-26 US disclosed
WO-2023170687-A1 BACTERIAL COMPOSITION FOR USE IN TREATMENT OF SUBSTANCE USE DISORDER BAR-ILAN UNIVERSITY (IL) 2023-09-14 WO disclosed
CN-110187016-A A kind of analysis method of cassie letones in dried blood sample 司法鉴定科学研究院 2019-08-30 CN disclosed
US-9938276-B2 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2018-04-10 US disclosed
US-20170320874-A1 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-09 US disclosed
US-9671415-B2 Immunoassay for pyrrolidinophenones RANDOX LABORATORIES LIMITED (GB) 2017-06-06 US disclosed
US-20160097783-A1 IMMUNOASSAY FOR PYRROLIDINOPHENONES NORTHERN BANK LIMITED (IE) 2016-04-07 US disclosed
US-8399480-B2 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-03-19 US disclosed
US-20120258963-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. 2012-10-11 US disclosed
US-20110028481-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. 2011-02-03 US disclosed
US-20090253705-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2009-10-08 US disclosed
EP-0150235-A1 Derivatives of 3-pyrrolidinopropiophenone and a process for preparation thereof Hokuriku Pharmaceutical Co.,Ltd (JP) 1985-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028481-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 NPC1 2654/4885MAPT 3296/4885ALDH1A1 369/4885
US-20120258963-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 NPC1 2654/4885MAPT 3296/4885ALDH1A1 369/4885
US-20090253705-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 NPC1 2654/4885MAPT 3296/4885ALDH1A1 369/4885
US-20160097783-A1 IMMUNOASSAY FOR PYRROLIDINOPHENONES CYP2D6, CYP2B6, CYP3A43 NPC1 4602/4885MAPT 2162/4885ALDH1A1 306/4885
US-20170320874-A1 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY5R NPC1 1014/4885MAPT 1128/4885ALDH1A1 2028/4885
US-20260086062-A1 IMMOBILIZATION STRATEGIES FOR ENHANCING SENSITIVITY OF ELECTROCHEMICAL APTAMER-BASED SENSORS EBPL, ADA, XBP1 NPC1 4559/4885MAPT 1108/4885ALDH1A1 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.